Identification and validation of TSPAN13 as a novel temozolomide resistance-related gene prognostic biomarker in glioblastoma.
Glioblastoma (GBM) is the most lethal primary tumor of the central nervous system, with its resistance to treatment posing significant challenges. This study aims to develop a comprehensive prognostic model to identify biomarkers associated with temozolomide (TMZ) resistance. We employed a multiface...
Saved in:
Main Authors: | Haofei Wang, Zhen Liu, Zesheng Peng, Peng Lv, Peng Fu, Xiaobing Jiang |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2025-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0316552 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Associated adverse outcomes with tumor treating fields when combined to temozolomide versus temozolomide alone for the treatment of glioblastoma: a meta-analysis of randomized trials
by: Yuanyuan Chen, et al.
Published: (2025-02-01) -
Magnetic and pH sensitive nanocomposite microspheres for controlled temozolomide delivery in glioblastoma cells
by: Meysam Ahmadi, et al.
Published: (2024-12-01) -
Synergism of d-limonene and temozolomide on migratory and apoptotic behaviors of human glioblastoma cell lines
by: Megha Gautam, et al.
Published: (2024-09-01) -
Improved Outcomes with Intensity Modulated Radiation Therapy Combined with Temozolomide for Newly Diagnosed Glioblastoma Multiforme
by: Noel J. Aherne, et al.
Published: (2014-01-01) -
Retraction Note: Tspan8 and Tspan8/CD151 knockout mice unravel the contribution of tumor and host exosomes to tumor progression
by: Kun Zhao, et al.
Published: (2025-01-01)